Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Pesqui. bras. odontopediatria clín. integr ; 19(1): 4350, 01 Fevereiro 2019. tab
Article in English | LILACS, BBO - Dentistry | ID: biblio-997959

ABSTRACT

Objective: To compare salivary transferrin levels between patients with oral lichen planus (OLP) and healthy subjects. Material and Methods: In this descriptive, analytical, crosssectional study, 11 patients with OLP and 22 healthy subjects were selected after matching in terms of age and gender. OLP was confirmed by two oral medicine specialists based on clinical and histopathological criteria. Salivary samples were collected by spitting. The patients were asked to collect their saliva in their oral cavity and then evacuate it into sterilized Falcon tubes. The procedure was repeated every 60 seconds for 5-15 minutes. A total of 5 mL of saliva was collected using this method. The samples were collected from 8 to 9 in the morning in a fasting state to avoid circadian changes. The collected salivary samples were immediately placed next to ice and transferred to the laboratory to be centrifuged at 4°C at 800 g to isolate squamous cells and cellular debris. Then the samples were frozen at -80°C until the samples were prepared. An ELISA kit was used to determine salivary transferrin levels. Data were analyzed with descriptive statistics (means and standard deviations) and t-test for independent groups using SPSS 17. Statistical significance was set at p<0.05. Results: The mean salivary transferrin concentrations in patients with OLP and healthy subjects were 0.9055±0.28229 and 1.5932±0.80041 mg/dL, respectively (p<0.05). Conclusion: The salivary transferrin levels in patients with OLP were significantly lower than those in healthy subjects.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Saliva , Transferrin , Clinical Diagnosis , Lichen Planus, Oral/diagnosis , Mouth Diseases/diagnosis , Case-Control Studies , Epidemiology, Descriptive , Cross-Sectional Studies/methods , Histological Techniques/methods , Iran
2.
Nutr Cancer ; 71(3): 444-451, 2019.
Article in English | MEDLINE | ID: mdl-30616380

ABSTRACT

OBJECTIVE: Gastric cancer is the third-leading cause of cancer-related mortality and the fifth most common cancer globally. Polyunsaturated fatty acids (PUFAs) are considered as functional ingredients that improve the efficacy of chemotherapeutic drugs. The aim of this study is to investigate the effect of PUFAs administration on matrix metalloproteinases (MMPs). METHODS: This study was designed as a randomized, double-blind trial. Thirty-four newly diagnosed patients with gastric cancer were randomly divided into two groups: control group (n = 17) and case group (n =17). Both groups received the same dose (75 mg/m2) of cisplatin. Control group received cisplatin plus placebo and the case group received cisplatin plus PUFAs [3600 mg/day, for three courses (each course included 3 weeks)]. The mRNA and protein expression of MMPs determined by real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC), respectively. RESULTS: The relative gene expression of MMP-1 and MMP-9 was significantly lower in case group than control. The protein expression of MMP-1 and MMP-9 was significantly lower in case group than control. CONCLUSION: According to the results of this study, PUFAs reduced the expression of MMPs in gastric cancer cells. It seems that PUFAs may have an inhibitory effect on invasion and metastasis of gastric cancer cells.


Subject(s)
Adenocarcinoma/drug therapy , Cisplatin/therapeutic use , Fatty Acids, Unsaturated/administration & dosage , Gene Expression/drug effects , Matrix Metalloproteinases/genetics , Stomach Neoplasms/drug therapy , Adenocarcinoma/enzymology , Aged , Aged, 80 and over , Double-Blind Method , Female , Humans , Male , Matrix Metalloproteinase 1/analysis , Matrix Metalloproteinase 1/genetics , Matrix Metalloproteinase 9/analysis , Matrix Metalloproteinase 9/genetics , Middle Aged , Neoplasm Invasiveness/prevention & control , Neoplasm Metastasis/prevention & control , RNA, Messenger/analysis , Stomach Neoplasms/enzymology
3.
Pesqui. bras. odontopediatria clín. integr ; 18(1): 4343, 15/01/2018. tab, graf
Article in English | LILACS, BBO - Dentistry | ID: biblio-967097

ABSTRACT

Objective: To compare salivary levels of PAI-2 in patients with moderate generalized chronic periodontitis before and after treatment and healthy subjects. Material and Methods: The present case-control study evaluated patients with generalized moderate chronic periodontitis (the case group) and subjects with healthy gingiva (the control group). The healthy subjects were evaluated once and the cases were evaluated twice (before and after treatment) by collecting their salivary samples. ELISA technique was used to determine PAI-2 salivary levels. Data were analyzed with the use of SPSS 17. The level of significance was set at 5%. Results: The mean salivary levels of PAI-2 in the case and control groups were 45.63 ± 8.63 and 22.01 ± 9.77 ng, respectively (p<0.0001). In addition, PAI-2 salivary levels in the case group subjects after treatment was 27.43 ± 5.79 ng, which was lower than that before treatment (45.63 ± 8.63 ng) (p<0.0001). The mean salivary level of PAI-2 in subjects with periodontitis after treatment (27.43 ± 5.79) was not significantly different from that in healthy subjects (22.01 ± 9.77) (p>0.05). Conclusion: The salivary levels of PAI-2 in patient with moderate generalized chronic periodontitis were higher than these in healthy subjects. However, the salivary levels of PAI-2 decreased in the case group subjects after treatment, with no significant difference from the healthy subjects.


Subject(s)
Humans , Male , Female , Adult , Saliva , Enzyme-Linked Immunosorbent Assay , Plasminogen Activators/antagonists & inhibitors , Case-Control Studies , Chronic Periodontitis/diagnosis , Periodontitis/etiology , Data Interpretation, Statistical , Iran
4.
Lipids ; 52(6): 549-558, 2017 06.
Article in English | MEDLINE | ID: mdl-28493185

ABSTRACT

Drug-resistant strains of Helicobacter pylori and poor treatment response are the main reasons for the failure in eradicating it in patients. Polyunsaturated fatty acids (PUFA) have an inhibitory effect on bacterial growth. The aim of this study was to investigate the effect of PUFA in combination with standard triple therapy on apoptosis in H. pylori infected subjects with dyspeptic symptoms. This study was a double-blind clinical trial in which 34 H. pylori infected subjects with dyspeptic symptoms were randomly divided into two groups of 17 patients. The control group received standard triple therapy (amoxicillin, clarithromycin and omeprazole) and the experimental group received the standard therapy and PUFA for two weeks. Gene expression levels of caspase-3, BCL-2 and Bad proteins were studied with real-time PCR, while protein levels were quantified in frozen sections and using immunohistochemistry. Compared with the control group, a significant increase (p < 0.01) was observed in the expression of caspase-3 and Bad genes and a significant reduction (p < 0.05) in the expression of Bcl-2 gene. The protein level of active caspase-3 and Bad protein was significantly increased and the level of Bcl-2 protein was significantly decreased (p < 0.05). The results of this study show that oral administration of PUFA in combination with the standard triple therapy increased apoptosis in H. pylori-infected patients with dyspeptic symptoms. This increase in apoptosis may partly reduce drug resistance in these patients. Our results suggest inclusion of a dietary PUFA containing fatty acid supplement may improve treatment of patients that are refractory to the standard triple therapy.


Subject(s)
Dyspepsia/complications , Dyspepsia/therapy , Fatty Acids, Unsaturated/therapeutic use , Helicobacter Infections/complications , Helicobacter Infections/therapy , Helicobacter pylori/drug effects , Stomach/drug effects , Adult , Aged , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Apoptosis , Caspase 3/genetics , Clarithromycin/therapeutic use , Dietary Fats, Unsaturated/therapeutic use , Double-Blind Method , Dyspepsia/genetics , Dyspepsia/pathology , Female , Gene Expression Regulation/drug effects , Helicobacter Infections/genetics , Helicobacter Infections/pathology , Humans , Male , Middle Aged , Omeprazole/therapeutic use , Proto-Oncogene Proteins c-bcl-2/genetics , Stomach/pathology
5.
Anticancer Agents Med Chem ; 17(1): 93-101, 2017.
Article in English | MEDLINE | ID: mdl-27198984

ABSTRACT

OBJECTIVE: Gastric cancer is the fourth most common cancer and the second cause of death in the world. According to the studies, the gastric cancer is relatively sensitive to chemotherapy. The aim of this study was to investigate the association of oral administer PUFAs with Caspase enzymes in patients with gastric cancer under chemotherapy. METHODS: This study was a Clinical Trial in which the target group consisted of the patients recognized with gastric cancer for the first time and cured under chemotherapy. Thirty-four patients were selected and categorized randomly into two groups. The case group included the patients taking PUFAs along with chemotherapeutic agent. In these patients, chemotherapy started with Cis-Platin plus PUFAs supplement in the scale of 3600 mg daily and in three courses. In control group, the individuals were under the same chemotherapy protocol without PUFAs. Biopsy samples from tumor were taken from the patients before and after chemotherapy. Levels of mRNA and protein expression of caspase 3, 8, 9 were measured in biopsy samples by Real-Time PCR and Frozen Section methods. The levels of apoptosis were determined using DNA-damage colorimetric assay. RESULTS: In the case group, caspase 3 showed a significant increase in both gene and protein expression levels after administration of PUFAs supplement in comparison with those of the control group (p=0.006 for gene, p=0.001 for protein). PUFAs induced caspase-9 gene expression level in these patients (p<0.0001). Caspase-9 protein level also revealed a marked elevation when PUFAs were administered along with chemotherapeutic agent (p<0.0001). DNA damage in gastric tissue from the patients under PUFAs treatment plus Cis-Platin was significantly higher than that of control group (p=0.003). PUFAs showed no significant changes in caspase-8 both at the gene and protein levels in the patients. CONCLUSION: According to the results of present study, it appears that oral administration of PUFAs can elevate the efficacy of chemotherapy agent in individuals' mitochondria-dependent apoptosis. As PUFAs enhances caspase-3 and 9 genes expression levels, which is an important induce the mitochondrial dependent apoptosis process. The study was registered in Iran clinical trials registry center under No. IRCT2014031016922N1.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/therapeutic use , Caspases/analysis , Fatty Acids, Unsaturated/therapeutic use , Stomach Neoplasms/drug therapy , Stomach/drug effects , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Administration, Oral , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Apoptosis/drug effects , Caspase 3/genetics , Caspase 8/genetics , Caspase 9/genetics , Caspases/genetics , DNA Damage/drug effects , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-3/therapeutic use , Fatty Acids, Omega-6/administration & dosage , Fatty Acids, Omega-6/therapeutic use , Fatty Acids, Unsaturated/administration & dosage , Female , Gastric Mucosa/metabolism , Humans , Male , Middle Aged , Stomach/pathology , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Up-Regulation/drug effects
6.
J Res Med Sci ; 21: 10, 2016.
Article in English | MEDLINE | ID: mdl-27904556

ABSTRACT

BACKGROUND: Studies show that polyunsaturated fatty acids (PUFAs) may have an inhibitory role in carcinogenesis. It was previously shown that PLA2 group 2A (PLA2G2A) messenger RNA (mRNA) expression is associated with less frequent metastasis and longer survival in gastric adenocarcinoma. This study intends to investigate the effect of PUFAs on the expression of PLA2G2A in patients with gastric cancer. MATERIALS AND METHODS: Thirty-four patients with gastric cancer (GC) were randomly divided into two groups. The first group received cisplatin medication. The second group received cisplatin medication and supplements of ω-fatty acids for three courses. The total RNA was extracted from the tissues and cDNA was synthesized. The gene expression of PLA2G2A was evaluated by the real-time polymerase chain reaction (PCR) method. To confirm the changes in gene expression, frozen section was utilized. The frozen tissue samples were sectioned and stained using the immunohistochemistry technique. RESULTS: After chemotherapy and chemotherapy plus supplement, the relative mean of PLA2G2A gene expression increased 1.5 ± 0.5-fold and 7.4 ± 2.6-fold, respectively (P = 0.006). The relative mean of gene expression in patients who received cisplatin and ω-fatty acids supplement increased more significantly (7.5 ± 3.3-fold) than in patients who received only cisplatin (P = 0.016). CONCLUSION: It was found that PUFAs increased the gene and protein expression of PLA2G2A in gastric cancer. Concerning the fact that studies reveal protective function of PLA2G2A in gastric cancer, it is suggested that increased expression of PLA2G2A is helpful. Furthermore, PUFAs can be considered as a useful therapeutic supplement for patients with gastric cancer.

SELECTION OF CITATIONS
SEARCH DETAIL
...